Ferro Desideri, Lorenzo

Up a level
Export as [feed] RSS
Group by: Date | Item Type | Refereed | No Grouping
Jump to: 2024 | 2023

2024

Anguita, Rodrigo; Roth, Janice; Ferro Desideri, Lorenzo; Makuloluwa, Achini; Katta, Mohamed; Shahid, Syed; Olvera-Barrios, Abraham; Charteris, David G (2024). Spontaneous suprachoroidal haemorrhage: clinical features, visual outcomes and prognosis factors. (In Press). Eye Springer Nature 10.1038/s41433-024-03278-9

Anguita, Rodrigo; Downie, Catriona; Ferro Desideri, Lorenzo; Sagoo, Mandeep S (2024). Assessing large language models' accuracy in providing patient support for choroidal melanoma. (In Press). Eye Springer Nature 10.1038/s41433-024-03231-w

Ferro Desideri, Lorenzo; Anguita, Rodrigo; Berger, Lieselotte E; Feenstra, Helena M A; Scandella, Davide; Sznitman, Raphael; Boon, Camiel J F; van Dijk, Elon H C; Zinkernagel, Martin S (2024). Analysis of optical coherence tomography biomarker probability detection in central serous chorioretinopathy by using an artificial intelligence-based biomarker detector. International journal of retina and vitreous, 10(42) BMC 10.1186/s40942-024-00560-6

Ferro Desideri, Lorenzo; Arun, Kirupakaran; Doherty, Grace; Bernardi, Enrico; Anguita, Rodrigo (2024). Iris Reconstruction: A Surgeon's Guide. Journal of clinical medicine, 13(9) MDPI 10.3390/jcm13092706

Kumar, Aneeta; Ferro Desideri, Lorenzo; Ting, Magdalene Yin Lin; Anguita, Rodrigo (2024). Perspectives on the currently available pharmacotherapy for wet macular degeneration. Expert opinion on pharmacotherapy, 25(6), pp. 755-767. Informa Healthcare 10.1080/14656566.2024.2354921

Ferro Desideri, Lorenzo; Artemiev, Dmitri; Zandi, Souska; Zinkernagel, Martin S; Anguita, Rodrigo (2024). Proliferative vitreoretinopathy: an update on the current and emerging treatment options. Graefe's archive for clinical and experimental ophthalmology, 262(3), pp. 679-687. Springer 10.1007/s00417-023-06264-1

Ferro Desideri, L; Anguita, R (2024). Mirror hypopyon in a patient with silicone oil tamponade and an active corneal ulcer. (In Press). Journal français d'ophtalmologie, 47(5), p. 104045. Elsevier Masson SAS 10.1016/j.jfo.2023.104045

Ferro Desideri, Lorenzo; Anguita, Rodrigo; Berger, Lieselotte E; Feenstra, Helena M A; Scandella, Davide; Sznitman, Raphael; Boon, Camiel J F; van Dijk, Elon H C; Zinkernagel, Martin S (2024). BASELINE SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHIC RETINAL LAYER FEATURES IDENTIFIED BY ARTIFICIAL INTELLIGENCE PREDICT THE COURSE OF CENTRAL SEROUS CHORIORETINOPATHY. Retina, 44(2), pp. 316-323. Wolters Kluwer 10.1097/IAE.0000000000003965

Forte, Paolo; Ferro Desideri, Lorenzo; Manocchio, Riccardo; Corazza, Paolo; Traverso, Carlo Enrico; Nicolò, Massimo (2024). Prechoroidal Cleft Regression After Switch to Intravitreal Brolucizumab. European journal of ophthalmology, 34(1), NP123-NP126. Sage Publications 10.1177/11206721231185903

2023

Ferro Desideri, Lorenzo; Roth, Janice; Zinkernagel, Martin; Anguita, Rodrigo (2023). "Application and accuracy of artificial intelligence-derived large language models in patients with age related macular degeneration". International journal of retina and vitreous, 9(1), p. 71. BMC 10.1186/s40942-023-00511-7

Ferro Desideri, L; Anguita, R (2023). Decompression retinopathy. Journal français d'ophtalmologie, 46(9), pp. 1127-1128. Elsevier Masson SAS 10.1016/j.jfo.2023.05.004

Ferro Desideri, Lorenzo; Artemiev, Dmitri; Bernardi, Enrico; Paschon, Karin; Zandi, Souska; Zinkernagel, Martin; Anguita, Rodrigo (2023). Investigational drugs inhibiting complement for the treatment of geographic atrophy. Expert opinion on investigational drugs, 32(11), pp. 1009-1016. Taylor & Francis 10.1080/13543784.2023.2276759

Ferro Desideri, Lorenzo; Zandi, Souska; Zinkernagel, Martin S; Anguita, Rodrigo (2023). Challenges in proliferative vitreoretinopathy: is biological therapy a solution? Expert opinion on biological therapy, 23(10), pp. 937-939. Taylor & Francis Group 10.1080/14712598.2023.2248881

Ferro Desideri, Lorenzo; Traverso, Carlo Enrico; Nicolò, Massimo; Munk, Marion R (2023). Faricimab for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration. Pharmaceutics, 15(5) MDPI 10.3390/pharmaceutics15051413

Provide Feedback